10-QPeriod: Q2 FY2022

Merck & Co., Inc. Quarterly Report for Q2 Ended Jun 30, 2022

Filed August 5, 2022For Securities:MRK

Summary

Merck & Co., Inc. (MRK) reported strong financial results for the quarter ended June 30, 2022. Net sales increased significantly year-over-year, driven by robust performance across key franchises, particularly in Oncology (Keytruda) and Vaccines (Gardasil/Gardasil 9). The company also saw substantial contributions from its antiviral medication Lagevrio. Despite increased costs, especially related to the collaboration with Ridgeback for Lagevrio, Merck maintained healthy profitability. The company's strategic investments in research and development and business development initiatives, including collaborations in July 2022 for ODM-208 and MK-1200, position it for future growth. Merck also reiterated its full-year 2022 sales guidance for Lagevrio, expecting between $5.0 billion and $5.5 billion.

Financial Highlights

53 data points
Beta

Revenue

$14.59B

71.1% Gross Margin

Net Income

$3.94B

27.0% Net Margin

EPS (Diluted)

$1.55

Total Assets

$107.09B

Cash & Equivalents

$9.75B

Free Cash Flow

$4.30B

Financial Statements
Beta
Revenue$14.59B
Cost of Revenue$4.22B
Gross Profit$10.38B
R&D Expenses$2.80B
SG&A Expenses$2.51B
Operating Income$8.25B
Interest Expense$240.00M
Net Income$3.94B
EPS (Basic)$1.56
EPS (Diluted)$1.55
Shares Outstanding (Basic)2.53B
Shares Outstanding (Diluted)2.54B

Key Highlights

  • 1Merck reported a substantial increase in net sales, up 28% year-over-year to $14.6 billion for the quarter, driven by strong product demand and contributions from Lagevrio.
  • 2Keytruda sales continued their upward trajectory, growing 26% to $5.3 billion, supported by new indications and strong global uptake.
  • 3The Vaccines segment showed robust growth, with Gardasil/Gardasil 9 sales up 36% to $1.7 billion, indicating strong demand for HPV vaccines.
  • 4Lagevrio, an antiviral COVID-19 medicine, generated $1.2 billion in sales for the quarter, contributing significantly to the company's top-line growth.
  • 5Research and Development expenses decreased by 35% year-over-year, primarily due to a large acquisition-related charge in the prior year, while strategic investments in new collaborations continue.
  • 6The company continues to actively manage its pipeline with new collaborations announced in July 2022 for ODM-208 (oncology) and MK-1200 (oncology), indicating a focus on innovation.
  • 7Merck maintained a strong liquidity position with $10.4 billion in cash and investments at quarter-end and generated $9.1 billion in operating cash flow for the first six months of 2022.

Frequently Asked Questions

Sales growth was primarily driven by strong performance in the Oncology franchise (Keytruda), substantial sales from the antiviral COVID-19 medicine Lagevrio, and robust demand for the Gardasil/Gardasil 9 vaccines. Higher sales of hospital acute care products and increased alliance revenues from collaborations also contributed.

R&D expenses decreased by 35% year-over-year for the quarter. This decrease was primarily due to a significant charge in the prior year related to the acquisition of Pandion Therapeutics, Inc. Despite the year-over-year decrease, Merck continues to invest in its pipeline and has entered into new collaborations, demonstrating a commitment to future innovation.

Merck reiterated its full-year 2022 sales guidance for Lagevrio to be between $5.0 billion and $5.5 billion, indicating continued expected demand for the COVID-19 antiviral medicine.

Merck is involved in various legal proceedings, including product liability litigation (e.g., Fosamax, Januvia/Janumet) and antitrust litigation (e.g., Zetia). The company also noted its challenge to a letter from HRSA regarding its 340B Program integrity initiative. While the company believes the resolution of most matters will not be material, ongoing litigation, particularly patent-related challenges for key drugs like Januvia, could impact future exclusivity and sales.